Upon vascular damage, coagulation is initiated by extravascular tissue factor (TF).
Introduction
The clotting of blood is a complex and well regulated process, requiring coagulation factors, calcium ions, a membrane surface exposing phosphatidylserine, and tissue factor (TF), the initiator of coagulation activation. TF is mainly present outside the vasculature under physiological conditions, and this TF contacts the blood only upon vascular injury. Within the blood, a low concentration of non-coagulant "blood-borne" TF is present under physiological conditions. This intravascular TF is associated with circulating cell-derived microparticles 1 and may become coagulant by disulfide isomerization. [2] [3] [4] Under pathological conditions, high levels of coagulant TF-exposing microparticles can be present within the blood. The presence of monocyte-derived microparticles exposing coagulant TF has been associated with disseminated intravascular coagulation (DIC), 5 and TF-exposing microparticles in human wound blood during open heart surgery triggered TFdependent thrombus formation in a rat venous stasis model, directly demonstrating that TFexposing microparticles can trigger coagulation in vivo. 6;7 More recently, the presence of microparticles exposing coagulant TF has been associated with the high incidence of venous thromboembolism in cancer patients. [8] [9] [10] Intravascular TF-exposing microparticles may initiate thrombus formation directly or indirectly. Whereas TF-exposing microparticles can directly initiate coagulation and thrombus formation, cancer cell-derived microparticles exposing TF and PSGL-1 (P-selectin glycoprotein ligand-1) were shown recently to induce thrombus formation by binding to activated platelets at a site of vascular injury in vivo. 11 The prothrombotic state in this mouse model was reduced by antibodies against P-selectin, implicating that circulating microparticles initiate coagulation after binding to activated platelets or endothelial cells exposing P-selectin.
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Blood and other body fluids contain several different types of cell-derived vesicles. 14 The most widely studied types of vesicles are microparticles and exosomes. Microparticles are released from the plasma membrane by a "budding" process and typically range in size between 100 nm and 1 µm. Exosomes are smaller than microparticles and range in size between 30 -90 nm, and become released when membranes of multivesicular bodies fuse with the plasma membrane. Typically, exosomes contain heat-shock proteins and often but not always expose tetraspanins such as CD63, 15 although CD63 can also be exposed on e.g.
microparticles from degranulated platelets. Furthermore, several body fluids, including saliva, contain P4 particles, also known as membrane particles, 14 which originate from epithelial cells and are of similar size as exosomes. These particles were reported to expose prominin-1 (CD133) but to lack CD63. [16] [17] [18] Throughout this manuscript, we will use the term exosomes for both exosomes and P4 (membrane) particles in saliva, unless stated otherwise.
Blood is not our only body fluid that can contains TF-exposing coagulant microparticles. Previously, we demonstrated that synovial fluid from arthritic patients also contains such microparticles. 19;20 When we have a wound, for instance a bleeding finger, our reflex is to put this finger in our mouth. In this way, blood is directly exposed to saliva. This reflex has previously been explained by the presence of antimicrobial and wound healing compounds, such as histatin, in saliva. 21 We hypothesized that there may be an alternative explanation for this reflex. For over 70 years, human saliva has been known to contain a compound that efficiently triggers coagulation. 22 In fact, already in 1960 it was observed that "human saliva accelerates the prothrombin time as much as snake venom does". 23;24 In the 1990's, the TF antigen was shown to be present in saliva and other human body fluids, but its coagulant activity was not investigated. 25 This raised the question whether TF in saliva is also capable of initiating coagulation, and thus can be an additional source of extravascular TF that 
Methods

Antibodies and reagents
Anti-factor VII (clone CLB VII-1), anti-factor XII (clone CLB OT2) and anti-CD63 were obtained from Sanquin (Amsterdam, The Netherlands). Anti-TF (anti-CD142) 4502 was 
Collection of blood and saliva
Citrate-anticoagulated blood (0.32%) was collected from 10 healthy subjects with informed consent after overnight fasting by venapuncture without a tourniquet through a 19-gauge needle using a Vacutainer system (5 males and 5 females; age 40 ± 16). Concurrently, saliva was collected from the same subjects and immediately placed on melting ice. To remove cells, saliva and blood were centrifuged (1,550 g, 20 minutes) at 4 °C (saliva) or 20 °C (blood) to prepare cell-free saliva and plasma. Saliva and plasma were both placed on melting ice, and 
Isolation of cell-derived microparticles and exosomes
Cell-free saliva and plasma samples (250 µl) were centrifuged for 30 minutes at 18,890 g and 4 °C to isolate microparticles. In turn, to obtain exosomes, the microparticle-depleted supernatant (225 µl) was centrifuged for 1 hour at 154,000 g and 4 °C in 1.5 ml polyallomer microfugetubes in a Optima TM Max ultracentrifuge using a TLA-55 rotor from Beckman Instruments (Fullerton, CA). The exosome-depleted supernatants (200 µl) from saliva and plasma were collected, and supernatants as well as isolated fractions of microparticles (25 µl) and exosomes (25 µl) were stored on melting ice until use.
Measurement of TF, coagulation factors II, V, VII, VIII and X, and fibrinogen
To determine the levels of TF (antigen), coagulation factors and fibrinogen in human plasma and saliva, we used commercially available ELISA kits. TF kits were obtained from American Diagnostics (Stamford, CT), kits for coagulation factors II and VIII were from Dako (Glostrup, Denmark), and kits for coagulation factors V, VII, IX, X and fibrinogen were from Hyphen BioMed (Neuville-sur-Oise, France). All assays were performed as described by the manufacturers.
Measurement of the coagulant properties of saliva in the fibrin generation test
Autologous cell-free plasma, containing microparticles and exosomes (70 µl), was incubated with cell-free saliva (20 µl), i.e. saliva still containing microparticles and exosomes, for 5 minutes at 37 °C in a 96 well plate (n = 5). Similarly, autologous vesicle-depleted human plasma (1 hour at 154,000 g; 70 µl) was incubated with cell-free saliva (20 µl) or cell-free In control experiments, we compared the activity and specificity of anti-factor VII(a) and anti-TF in vesicle-depleted normal plasma to inhibit thromborel-and kaolin-induced fibrin generation. Both anti-factor VII(a) and anti-TF (4502) completely inhibited thromborelinduced fibrin generation, but did not inhibit kaolin-induced fibrin generation. Furthermore, both anti-factor VII(a) and anti-TF also completely inhibited fibrin generation induced by saliva or isolated fractions of vesicles from saliva in autologous vesicle-depleted plasma (n=3; data not shown). In the experiments described in this manuscript, we used anti-factor VII(a), since this antibody can be used at a lower concentration (1.0 µg/ml) than anti-TF (7.8 µg/ml) to completely inhibit TF-initiated coagulation. With regard to the specificity of anti-factor XII, we have previously demonstrated the specificity of this antibody in thrombin generation experiments, 26 and found similar results in the fibrin generation test (data not shown).
Measurement of the coagulant properties of microparticles and exosomes from saliva in the fibrin generation test
Fractions of isolated microparticles or exosomes (6 µl) were added to vesicle-depleted plasma (84 µl) and preincubated without or with antibodies similar to the experiments described in the previous paragraph. Coagulation was initiated and monitored as described above.
Thromboelastography
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From Into empty ROTEM cups, saline (3 µl), anti-factor VII (3 µl) or anti-factor XII (3 µl) were added. Subsequently, either saline (20 µl; control) plus CaCl 2 (20 µl; 0.1 M) or cell-free saliva (20 µl) plus CaCl 2 (20 µl; 0.1 M) were added, and clotting was started by addition of whole blood (300 µl). Clot formation was measured on a ROTEM (Phentapharm; Munich, Germany).
PAGE and Western blot
Western blots were stained for TF. Isolated fractions of microparticles and exosomes were resuspended in 25 µl reducing sample buffer, containing SDS and 6% β -mercapthoethanol.
All samples were boiled for 5 minutes. Samples (15 µl) were loaded on an 8 -16% gradient gel (Biorad, Hercules, CA) and blotted to Polyvinylidene Difluoride (PVDF) membrane (Millipore, Billerica, MA). Membranes were incubated with 5% protifar (Nutricia, Vienna, Austria) for 1 hour to reduce non-specific staining, followed by incubation with a mouse anti-TF (clone HTF-1, BD Pharmingen; San Diego, CA). A secondary antibody goat anti-mousehorseradish peroxidase (1:30,000; Dako; Glostrup, Denmark) was used. To visualize the bands, membranes were incubated with a 5-fold diluted peroxidase substrate (LumiLight;
Roche Diagnostics, Almere, the Netherlands) for 5 minutes, followed by analysis of luminescence using a LAS3000 luminescent image analyzer (Fuji; Valhalla, NY).
Transmission electron microscopy
Vesicles were resuspended in 0.1% paraformaldehyde (w/v). Fixed suspensions were used within five days. After fixation for at least 18 hours, the fractions were either negatively stained or labeled with immunogold. Grids were carbon evaporated before use. Vesicles were absorbed on grids by letting formvar-carbon coated grids float on drops of 10 µl fraction suspensions on a sheet of parafilm at room temperature for 7 minutes. Subsequent washing Finally, the grids were washed with 1x ECS solution before negative staining.
Flow cytometry
To estimate the concentrations of vesicles, isolated fractions of microparticles (25 µl) and exosomes (25 µl) were diluted with 100 µl citrate-containing PBS. From these suspensions and from the saliva or plasma depleted from vesicles (1 hour; 154,000 g), 5 µl aliquots were labeled by addition of one or more CD-specific monoclonal antibodies or the corresponding isotype-matched control antibodies (5 μ l per antibody). of microparticles and exosomes in saliva and plasma were estimated as described earlier. 27 It should be mentioned that the analysis of cell-derived vesicles, although the best method of choice at present, is stretching the capability of the flow cytometer, the size of these vesicles being near or below the detection limit of the technique. Thus, the side scatter will not accurately reflect the size of the vesicles and not all vesicles will be detected.
Statistics
Data were analyzed by two-tailed Student t-test (GraphPad Prism Software version 5.0;
GraphPad Software, Inc, CA). A probability value of < 0.05 was considered to be statistically significant. All data are shown as mean ± SD.
For
Results
Saliva contains TF but no coagulation factors or fibrinogen
Cell-free saliva from healthy subjects (n = 10) contained high levels of TF (1956 ± 610 pg/ml), but all other components required for coagulation were below the detection limit of the various assays (prothrombin (factor II), factors V, VII, IX, X and fibrinogen) or barely detectable (factor VIII; Figure 1A ). On the other hand, plasma contained a relatively low concentration of "blood-borne" TF (320 ± 311 pg/ml), but the concentrations of all other coagulation factors and fibrinogen were within their normal range ( Figure 1B) .
Saliva triggers factor VII-mediated coagulation of human plasma
We tested the ability of saliva to induce clot formation of autologous (vesicle-containing) plasma (n = 5). Addition of saliva shortened the clotting time from 1274 ± 197 s to 176 ± 42 s (P < 0.0001; Figure 2A ). Since human plasma from healthy subjects contains low levels of coagulant cell-derived vesicles, 26 we depleted plasma from all vesicles by ultracentrifugation to rule out a role for plasma vesicles in this model system. Figures 2B and 2C show representative curves obtained within a single experiment using plasma and saliva from one healthy subject. When vesicle-depleted plasma was recalcified, no plasma clot formation was observed for at least 3600 s ( Figure 2B ), indicating that this plasma was indeed free of vesicles. Upon addition of cell-free saliva, the clotting time of vesicle depleted plasma shortened to 228 ± 95 s (P < 0.0001; Figures 2B and 2D) . The saliva-induced shortening of the clotting time was completely abolished in the presence of anti-factor VII(a) (> 3600 s, P < 0.0001) but unaffected by anti-factor XII(a) (233 ± 101 s, P = 0.587; Figures 2C and 2D ).
Saliva contains cell-derived vesicles that initiate TF / factor VII-mediated coagulation activation of human plasma
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To investigate whether TF is associated with subpopulations of cell-derived vesicles in saliva, we subjected cell-free saliva to ultracentrifugation. After ultracentrifugation, the supernatant (SN) saliva was unable to shorten the clotting time of the vesicle-depleted plasma ( Table 1) , indicating that the coagulant activity of saliva is completely associated with cell-derived vesicles. Subsequently, we isolated microparticles and exosomes from cell-free saliva by differential centrifugation. Microparticles from saliva shortened the clotting time ( Figure 3A) , which was unaffected by anti-factor XII ( Figure 3A ; Table 1 , P = 0.272) but completely inhibited by anti-factor VII ( Figure 3A ; Table 1 ; P < 0.0001). Similarly, also exosomes shortened the clotting time ( Figure 3B ), and also this shortening was unaffected by anti-factor XII ( Figure 3B ; Table 1 ; P = 0.284) and completely inhibited by anti-factor VII ( Figure 3B ; Table 1 ; P = 0.016). Thus, cell-derived vesicles present in saliva initiate TF / factor VIIdependent coagulation.
For comparison, we also isolated microparticles and exosomes from the corresponding plasma samples. Plasma microparticles shortened the clotting time from > 3600 s to 2675 ± 849 s ( Figure 3C , P = 0.028). The extent of inhibition by anti-factor VII and anti-factor XII differed between subjects, but no net inhibition was observed when the overall data were analyzed (Table 1 ; P = 0.464 and P = 0.403, respectively). Addition of plasma exosomes did not affect the clotting time ( Figure 3D ).
TF in saliva is associated with microparticles and exosomes
To further investigate the association between TF and vesicles in saliva, we fractionated cellfree saliva in microparticles, exosomes and vesicle-depleted saliva, and determined the presence of TF. Figure 4A shows that TF antigen is associated with microparticles and exosomes, but is absent in the corresponding vesicle-depleted saliva. Please note that there was a considerable variation between subjects. The association between TF and cell-derived Figure 4B ) and transmission electron microscopy (TEM; Figure 4C ).
The cellular origin of cell-derived vesicles in saliva and plasma
In preliminary experiments, we determined the origin of the cells present in saliva. Both epithelial cells and granulocytes could be identified. Figures 5A and 5B show that most cellderived vesicles in saliva originate from these cell types, whereas relatively very low numbers expose CD61 (platelets, possibly also granulocytes), CD235a (erythrocytes) or CD20 (Blymphocytes). On the other hand, microparticles in plasma originated predominantly from platelets (CD61 + ) and to a lesser extent from erythrocytes (CD235a + ; Figure 5C ). The levels of exosomes in plasma were very low and we were unable to establish their cellular origin ( Figure 5D ).
The cellular origin of TF-exposing vesicles in saliva
We double-labeled the two most abundant types of microparticles and exosomes present in saliva with anti-TF. The absolute (100%) values for TF-exposing microparticles and exosomes were 1.35 ± 1.42 x 10 6 /ml and 0.35 ± 0.32 x 10 6 /ml, respectively (Figures 5E and F). TF-exposing vesicles mainly originated from granulocytes and epithelial cells. Due to the fact that antibodies against Ema and CD66b are only commercially available with FITC labels, triple-labeling of TF-exposing vesicles with both these antibodies was not possible, and therefore we cannot exclude that part of these vesicles are of mixed lineage, i.e. fusion of vesicles, as has been described earlier.
28
TF in saliva may be associated with exosomes and P4 (membrane) particles
Since there was a considerable overlap with regard to the cellular origin of microparticles and exosomes by flow cytometry ( Figure 5E and F), we first investigated whether the differential centrifugation to separate both types of vesicles was successful. Therefore, we studied the relative presence of CD63 and CD133 in the fractions of microparticles and exosomes ( Figure   6A ), as CD63 and CD133 are markers of exosomes and P4 (membrane) particles, respectively.
Relatively few microparticles stained for CD133 or CD63 (Figure 6A ; 2.6 ± 2.3% and 12. 7 ± 6.7%, respectively). In contrast, 40.6 ± 15.2% and 64.6 ± 9.6% of the vesicles isolated by ultracentrifugation from the microparticle-depleted saliva stained for CD133 and CD63, respectively, indicating a 15-fold (CD133) and 5-fold (CD63) enrichment compared to microparticles (both P < 0.0001). The presence of (CD133-exposing) P4 (membrane) particles and (CD63-exposing) exosomes was confirmed by TEM ( Figure 6B and C, respectively). When we quantified the frequency of vesicles with a diameter < 100 nm that stained for CD133 or CD63, there was a 11-fold and 6-fold enrichment in these populations compared to the microparticles (> 100 nm). These data show that exosomes and P4 (membrane) particles are enriched in the fraction of vesicles isolated by ultracentrifugation compared to the fraction of microparticles isolated by high-speed centrifugation.
Of the TF-exposing exosomes and P4 (membrane) particles ( Figure 6D ), a fraction stained for CD63 but was negative for CD133, suggesting that these vesicles are likely to be exosomes (32.6%). A small fraction stained for CD133 but was negative for CD63, and these vesicles are most likely P4 (membrane) particles (2.8%). In addition, a major fraction stained for CD133 and CD63, possibly reflecting complexes of P4 (membrane) particles and exosomes that may have been formed during sample preparation (47.9%) or in vivo. The remainder of the TF-exposing vesicles seemed to be neither exosomes nor P4 particles, since these vesicles did not stain for either CD63 or CD133 (16.8%).
Biological activity of saliva
To establish whether or not saliva has a true physiological role as an additional extravascular source of TF, we used a whole blood clotting model (ROTEM thromboelastography). Figure   7A shows representative curves with blood collected from a healthy subject, incubated without or with cell-free saliva. Clotting was initiated by addition of CaCl 2 . The addition of saliva dramatically shortened the clotting time of whole blood. The overall data with 10 volunteers are summarized in Figure 7B , confirming that also in whole blood the salivatriggered shortening of the clotting time is entirely TF / factor VII-dependent and factor XIIindependent. When blood was incubated with vesicle-depleted saliva (supernatant in Figure   7B ), no shortening of the clotting time was observed, confirming that removal of cell-derived vesicles completely abolishes the ability of saliva to trigger whole blood clot formation.
To further investigate the role of saliva as an extravascular source of TF, we also collected wound (pericardial) blood from patients undergoing cardiac surgery. We used this blood as a model system to test the ability of saliva or fractions thereof to initiate or facilitate clotting of wound blood, which contains high levels of endogenous coagulant TF, capable of triggering coagulation in vitro and thrombus formation in vivo. 6;7 To investigate the ability of saliva to shorten the clotting time of this human wound blood, pericardial blood was collected from five patients undergoing cardiac surgery. The clotting time of the wound blood was 300 ± 96 s ( Figure 7C ), which was further shortened by addition of cell-free saliva to 186 ± 24 s (P = 0.031). Both the clotting time of pericardial blood without saliva or with saliva returned to normal levels in the presence of anti-factor VII (514 ± 211 s, P = 0.016 and 480 ± 227 s, P = 0.033, respectively). The clotting time of wound blood in the absence of saliva was considerably shorter than the clotting time of blood from control subjects (622 ± 135 s, Figure   7B , P = 0.0004), which is due to the presence of the coagulant TF-exposing vesicles in this
blood. Taken together, these data show that TF in saliva may be a physiologically relevant extravascular source of TF that can shorten the clotting time of human wound blood.
Finally, we compared the coagulant activity of TF in saliva to that of a snake venom from the Common Lancehead Bothrops atrox. This venom, reptilase, activates the final steps of the clotting cascade by converting soluble fibrinogen into insoluble fibrin. As shown in Figure 7D , saliva and reptilase (0.2 and 0.4 BU) similarly shortened the clotting time of whole blood from healthy subjects (P = 0.0003 and 0.0002, respectively), confirming the remarkable coagulant activity of human saliva.
Discussion
Saliva has often been associated with wound healing and cleaning, since it contains growth factors and histatin which promote wound healing 21;29;30 and has an anti-microbial activity. 31;32 Studies going back to the 1930's, however, showed that saliva also promotes the clotting of blood, but the underlying mechanism has remained hitherto obscure. 22 The results presented in our study show that TF in saliva is associated with microparticles and exosomes originating from a variety of cell types. Based on our data, we postulate that the reflex to put a bleeding finger into the mouth or to lick a wound may be an elegant mechanism by which spatially separated essential coagulation components are brought together. 21;30 Therefore, this reflex may not be solely induced by the antimicrobial and wound healing properties of saliva, or as a reflex to keep the environment clean of blood or to release the pain, but may also be due to the ability of saliva to promote coagulation.
Our present study shows that various types of TF-exposing vesicles seem to coexist in human saliva. Saliva contains microparticles, exosomes and P4 (membrane) particles exposing TF, but to which extent these different types of vesicles contribute to the observed TF-dependent coagulant activity will require additional studies, since the applied isolation procedure of differential centrifugation did not completely separate the various types of vesicles. A relatively large population of vesicles stained for CD133 and CD63, which may be clusters of P4 particles and exosomes, since we frequently observed such clusters by TEM. To establish the cellular origin, antibodies were used directed against CD66b (granulocytes), Ema (epithelial membrane antigen, epithelial cells), CD61 (integrin β 3 , platelets, possibly granulocytes in saliva), CD235a (glycophorin A, erythrocytes) and CD20 (B lymphocytes), or control antibody (IgG). Microparticles (E) and exosomes (F) from saliva were double-labeled with anti-TF plus antibodies against either CD66b or Ema, and analyzed by flow cytometry.
In A -D the data are provided as number of microvesicles per ml, in E and F the data are expressed as % of the total number of TF-exposing microparticles or TF-exposing exosomes (n = 10). 
